Abaxis (Nasdaq: ABAX) reported earnings on Jan. 26. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended Dec. 31 (Q3), Abaxis missed on revenues and missed expectations on earnings per share.

Compared to the prior-year quarter, revenue grew and earnings per share shrank significantly.

Margins shrank across the board.

Revenue details
Abaxis tallied revenue of $37.9 million. The nine analysts polled by S&P Capital IQ foresaw revenue of $40.7 million. Sales were 5.4% higher than the prior-year quarter's $35.9 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions.

EPS details
EPS came in at $0.13. The nine earnings estimates compiled by S&P Capital IQ predicted $0.16 per share. GAAP EPS of $0.13 for Q3 were 24% lower than the prior-year quarter's $0.17 per share.

Source: S&P Capital IQ. Quarterly periods. Figures may be non-GAAP to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 54.1%, 110 basis points worse than the prior-year quarter. Operating margin was 12.3%, 390 basis points worse than the prior-year quarter. Net margin was 7.5%, 320 basis points worse than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $42.7 million. On the bottom line, the average EPS estimate is $0.19.

Next year's average estimate for revenue is $159.1 million. The average EPS estimate is $0.59.

Investor sentiment
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 157 members out of 172 rating the stock outperform, and 15 members rating it underperform. Among 48 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 46 give Abaxis a green thumbs-up, and two give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Abaxis is outperform, with an average price target of $32.

The health-care investing landscape is littered with also-rans and a few major winners. Is Abaxis the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company Fool co-founder David Gardner believes will be a phenomenal success over the next few years. Click here for instant access to this free report.